SUPN Supernus Pharmaceuticals, Inc. Earnings per share for the last twelve months

Supernus Pharmaceuticals (SUPN) is expanding its neuropsychiatric presence by scaling Qelbree sales to capture niches in pediatric therapy and Parkinson's disease. The 12-month net income per share snapshot visualizes this growth, where the 3.63 metric serves as the target level. However, the steady cash flow from current prescriptions is offset by patent expiration risks and a dependence on the success of new developments.
Metric breakdowns and analytics for Supernus Pharmaceuticals (SUPN)

The robotization of packaging and mixing lines at Supernus Pharmaceuticals (SUPN) directly impacts the rolling annual earnings per share trend available for analysis on GURU.Markets. This indicator reflects the total net income over the last twelve months divided by the total number of outstanding shares, allowing investors to assess the actual efficiency of capital generation per share.